

05-13-04

IFW
P
CASE PH7493



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305489031US
Express Mail Label Number

May 12, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit:

QUAN ET AL.

Examiner:

APPLICATION NO: 10/796,396

FILED: MARCH 9, 2004

FOR: TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE
PROTEASE INHIBITORS

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE DECLARATION AND
PETITION FOR CORRECTION OF INVENTIONSHIP


Sir:


Applicants hereby submit a Substitute Declaration and a Petition for Correction of Inventorship, copies enclosed herewith, for the above-captioned matter.

The Commissioner is hereby authorized to charge the \$130.00 fee under 37 CFR § 1.17(i) and any additional fees that may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is here enclosed.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791
Date: May 12, 2004


Jing S. Belfield, Ph.D.
Attorney for Applicants
Reg. No. 45,914



DOCKET NO.: PH-7493

PATENT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305489031US
Express Mail Label Number

May 12, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Quan et al.

Examiner:

Serial No.: 10/796,396

Group Art Unit:

Filed: March 9, 2004

For: TETRAHYDROQUINOLINE DERIVATIVES
USEFUL AS SERINE PROTEASE INHIBITORS

Hon. Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

PETITION FOR CORRECTION OF INVENTORSHIP UNDER 37 CFR §1.48(a)

1. Now comes Dietmar Seiffert and Robert Knabb who deposes and says that their names were erroneously excluded as joint inventors on the above-identified application and he contributed to inventive aspects of the present invention claimed therein. This error occurred without deceptive intent.
2. It is requested that Dietmar Seiffert and Robert Knabb be added as an inventors of the above-identified application. Thus, the inventorship of the above-identified application should be changed from Mimi L. Quan, Cailan Wang, Jinglan Zhou, Jon J. Hangeland to Mimi L. Quan, Cailan Wang, Jinglan Zhou, Jon J. Hangeland, Dietmar A. Seiffert and Robert M. Knabb.


05/14/2004 TBESHAN1 00000002 193880 10796396
05/14/2004 TBESHAN1 00000008 193880 10796396
01 FC:1051 130.00 DA

05/17/2004 TBESHAN1 00000002 193880 10796396

01 FC:1460 130.00 DA

3. The fee set forth under 37 C.F.R. §1.17(i) is being included with this filing.
4. The undersigned petitioner declares further that all statements made herein of his own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.
5. Further, the deponent saith not.

Date: 4/20/04


Dietmar Seiffert

Date: 04/20/04


Robert Knabb

CONSENT OF ASSIGNEE UNDER 37 CFR §1.48(a)


6. Petitioner, Bristol-Myers Squibb Company, is the owner of the entire right, title, and interest in and to the invention claimed and disclosed in the above-identified application by virtue of assignment. Petitioner hereby consents to a change in inventorship in the above-identified application from Mimi L. Quan, Cailan Wang, Jinglan Zhou, Jon J. Hangeland to Mimi L. Quan, Cailan Wang, Jinglan Zhou, Jon J. Hangeland, Dietmar A. Seiffert and Robert M. Knabb.

CERTIFICATION UNDER 37 CFR §3.73(b)

I, the undersigned, certify that I am an individual empowered to act on behalf of the petitioner, Bristol-Myers Squibb Pharmaceutical Company, a corporation, the assignee of the entire right, title, and interest of the above-identified application by virtue of an Assignment from the inventors of the application. I further certify that the Assignment has been recorded in the U.S. Patent and Trademark Office at Reel No. 014590, Frame 0843, on May 3, 2004, that I have reviewed that Assignment recorded at the reel and frame, and that to the best of my knowledge and belief, title is in the above-noted assignee.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Date: May 12, 2004


Signature

Stephen B. Davis
Senior Counsel, Patents
Registration No. 26,693

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4338 (phone)
(609) 252-4526 (fax)

SUBSTITUTEDECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe I am an original, first and joint inventor of the subject matter which is claimed
and for which a patent is sought on the invention entitled

TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE
PROTEASE INHIBITORS

the specification of which was filed on March 9, 2004 as U.S. Application No. **10/796,396**.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims.

I acknowledge my duty to disclose all information which is known by me to be material to
the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign
application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any
PCT international application(s) designating at least one country other than the United States
listed below and have also listed below any foreign application(s) for patent or inventor's
certificate or any PCT international application(s) designating at least one country other than the
United States for the same subject matter and having a filing date before that of the application
the priority of which is claimed for that subject matter:

None

I hereby claim the benefit under 35 USC §119(e) of any United States provisional
application(s) listed below:

Application No.

Filing Date

60/453,812

March 11, 2003

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed
below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the

United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

None

I hereby appoint the attorneys and agents associated with **Customer No. 23914**, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all communications to the address associated with **Customer No. 23914**, which is currently Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ 08543-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FIRST JOINT INVENTOR:

Full name : Mimi L. Quan

Signature : Date : April 20, 2004
(MM/DD/YY)


Citizenship : United States of America

Residence : Yardley, Pennsylvania

P.O. Address : 1437 Innis Lane
Yardley, Pennsylvania 19076

SECOND JOINT INVENTOR:

Full name : Cailan Wang

Signature : Date : 04/20/04
(MM/DD/YY)

Citizenship : People's Republic of China

Residence : New Hope, Pennsylvania

P.O. Address : 114 Equestrian Drive
New Hope, Pennsylvania 18938

THIRD JOINT INVENTOR:

Full name : **Jinglan Zhou**

Signature : 

Date : 04/27/2004
(MM/DD/YY)

Citizenship : ~~People's Republic of China~~ United States of America


Residence : San Diego, California

P.O. Address : 4466 Shorepointe Way
San Diego, California 92130

JZ

FOURTH JOINT INVENTOR:

Full name : **Jon J. Hangeland**

Signature : 

Date : 04/21/04
(MM/DD/YY)


Citizenship : United States of America

Residence : Morrisville, Pennsylvania

P.O. Address : 234 Louise Drive
Morrisville, Pennsylvania 19067

FIFTH JOINT INVENTOR:

Full name : **Dietmar A. Seiffert**

Signature : 

Date : 04/20/04
(MM/DD/YY)


Citizenship : United States of America

Residence : Boothwyn, Pennsylvania

P.O. Address : 6 Creek View Ct.
Boothwyn, Pennsylvania 19061

SIXTH JOINT INVENTOR:

Full name : **Robert M. Knabb**

Signature : 

Date : 04/20/04
(MM/DD/YY)

Citizenship : United States of America

Residence : Avondale, Pennsylvania

P.O. Address : 14 Sullivan Chase Drive
Avondale, Pennsylvania 19311